Dense Deposit Disease
Welcome,         Profile    Billing    Logout  
 3 Companies   2 Products   2 Products   0 Mechanisms of Action   0 Trials   6 News 
  • ||||||||||  Trial withdrawal:  TP10 Use in Patients With C3 Glomerulopathy (C3G) (clinicaltrials.gov) -  Oct 27, 2016   
    P1,  N=0, Withdrawn, 
    Active, not recruiting --> Completed Recruiting --> Withdrawn
  • ||||||||||  Sulonex (sulodexide) / Alfasigma
    Enrollment change, Trial withdrawal:  Sulodexide Treatment in Patients With Dense Deposit Disease (clinicaltrials.gov) -  Jun 11, 2015   
    P1,  N=0, Withdrawn, 
    Recruiting --> Withdrawn N=20 --> 0 | Terminated --> Withdrawn
  • ||||||||||  recombinant human Complement Receptor Type 1 (CDX-1135) / Celldex
    Trial termination:  Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease (clinicaltrials.gov) -  Mar 5, 2014   
    P1,  N=1, Terminated, 
    N=20 --> 0 | Terminated --> Withdrawn Recruiting --> Terminated; Portfolio prioritization due to slow enrollment and variable spectrum of potential complement abnormalities in DDD patients.